National Cancer Institute begins phase II trial with Crolibulin in anaplastic thyroid cancer
EpiCept Corporation announced that the National Cancer Institute (NCI) has initiated a phase II trial with Crolibulin (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with Anaplastic Thyroid Cancer (ATC). Crolibulin is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumour activity in both preclinical and early clinical studies.

Cadila Pharmaceuticals Ltd. (CPL) Is one of India’s most reputed, research-based, techno-savvy pharmaceutical companies with a focus in the area of Formulations & APIs and having its Corporate Office at Bhat, Ahmedabad and State-of-art manufacturing facilities at Dholka, Ankleshwar, Kadi and Jammu accredited with USFDA, MHRA, TGA, MCA, MCC & WHO certifications.
Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia.
